Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A definite radar for both imo. I know I'm watching. And I'm certainly not a fortune teller.
My post on the 27th..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171048812
LIKE the RSI in the 80's. FOXO
GALT 1.32 resistance. Looks like it may have the momo to kick thru.
BGXX getting ready to go imo. 1.32
lmao, went the wrong way.
It had its P&D imo. but as long as it has volatility I'll play it.
BGXX
BGXX 1 day chart showing a squeeze coming. Has the PSAR back in play with it on the 1hr.
Took 1.31 for the possible push to close.
Who knows. Maybe pigs can fly.
TOVX 1.15 break out. AH offering??
GALT 1.28, SOLID reversal.
PLX 1.64, 1.74 breakout trigger. Watch this puppy next week.
imo
Radar EOSE see if the 50dma catches and holds it around 1.25 though the way things look it just may see the $ again.
Also looking closer at CEI and CNTX. HILS is another one. Just watching these. I continue to swing EVAX, it's been pretty predictable for .15 to .20 swings. Last buy 1.59.
Anyway, looks like I continue to talk to myself here. Must be the adhd.
I dug even deeper... The merger between Stemline & BERLIN-CHEMIE AG making them a subsidiary along with Context already in the mix making up part of the MENARINI Group was done back in 2020. Totally legit.
I would go on to say the only thing CNTX needs to do is get back in compliance with their listing requirements. Which, to me, looks completely possible. And SOON.
https://finance.yahoo.com/news/context-therapeutics-clinical-partner-stemline-123000936.html
https://www.sec.gov/Archives/edgar/data/1810515/000110465920071780/tm2021445d10_ex99a5e.htm
https://www.sec.gov/Archives/edgar/data/1810515/000110465920071780/tm2021445d10_sctota.htm
https://www.sec.gov/Archives/edgar/data/1264587/000110465920071879/tm2021445d15_s8pos.htm
There's more but I'm satisfied. There's still quite the gap to fill but it can save it for a rainy day. My alerts are set.
pipeline is strong and their cashflow is strong. 40M cash doesn't come close to what you're posting.
My search didn't come up with anything. I see merge potential if anything else.
Exactly. Gap and trap and new bagholders. Pick your stop loss price and stick to it. Thinking this will see an offering by Friday.
But that's just my WAG.
I'm thinking we're waiting on news that they'll be granted an extension.
Just my WAG.
I loaded 1.10. As much as I hate gaps this is solid news.
SNOA barely even has a float. Wowzers.
ONTX $1.09
Day's Change
0.2375 (27.91%)
Wasn't watching soon enough.
.50's looks to be the first real resistance for RDHL imo. They just issued a s* ton of shares and raised the AS. They need to pump it to sell into it.
IMO of course.
https://www.sec.gov/edgar/browse/?CIK=1553846&owner=exclude
Looks to me everything has about topped out and we're looking at a potential MAJOR reset. GDP +2.9%??? Really? I see red flags just about everywhere right now.
With that, I would think there would be even more of a run to solid holdings such as gold and silver. But they need a reset as well imo.
https://finance.yahoo.com/news/gold-hovers-around-1-930-210723086.html
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed, on November 22, 2022, ContraFect Corporation (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of September 30, 2022 was approximately $(3.1) million. The Company is also not currently in compliance with the Nasdaq continued listing requirement that the Company maintain a bid price for the Company’s common stock of above $1.00 per share (the “Bid Price Requirement”). Subsequent to the receipt of the Nasdaq Staff Deficiency Letter, and prior to the deadline set forth in such letter, the Company submitted a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1) to Nasdaq.
On January 20, 2023, the Nasdaq staff (“Staff”) informed the Company that the Staff had determined to deny the Company’s request for continued listing on the Nasdaq Capital Market (the “Staff Determination”) and that, unless the Company requests an appeal of such determination, trading of the Company’s common stock will be suspended at the opening of business on January 31, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on the Nasdaq Capital Market. In reaching its decision, the Staff indicated that its determination was based on concerns that the Company’s ability to raise additional capital through the exercise of recently issued warrants to purchase the Company’s common stock or other capital raising transactions, in order to cure the Company’s non-compliance with Nasdaq Listing Rule 5550(b)(1), were not within the Company’s control and such funds may be insufficient to sustain compliance over the long term.
The Company intends to request a hearing before a Nasdaq Hearings Panel (“Panel”) to appeal the Staff Determination. The Staff Determination letter indicates that the Company’s hearing request will stay the suspension of trading and delisting of the Company’s common stock pending the conclusion of the hearing process. Consequently, the Company’s common stock will remain listed on the Nasdaq Capital Market at least until the Panel renders a decision following the hearing. There can be no assurance that the Panel’s decision will grant the Company’s request for continued listing on The Nasdaq Capital Market.
The Company continues to evaluate various alternative courses of action to regain compliance with the Nasdaq Capital Market listing requirements. However, there can be no assurance that the Company will be able to satisfy the Nasdaq Capital Market’s continued listing requirements, regain compliance with the minimum stockholders’ equity requirement or the Bid Price Requirement, or maintain compliance with the other listing requirements.
https://ih.advfn.com/stock-market/NASDAQ/contrafect-CFRX/stock-news/90071670/current-report-filing-8-k
Down 25% PM.
This will be interesting to watch.
Looks like XSNX is owning up to owing a shortfall since the price has depreciated so much. Simply covering for more dilution.
JMHO.
See the modification/adjustment filing.
https://www.sec.gov/Archives/edgar/data/1039466/000118518523000060/ex_466623.htm
Both have made decent swings and may be setting up again soon. Adding PLX to the mix as well.
EVAX 1.60
PLX 1.43. Missed the dip yesterday. Maybe to try some patience. For once.
SONN 1.19 +.09
Looks like a discount is staring right at us!
Still good things happening so I'll be loading up again. Shorts are on top. S-1 filed. Chart looks like crap. Probably see the $ again, maybe a dip under... again. That's when I'll be looking closer.
Excerpt : "We have evaluated the drug levels and cytokine responses in the SB102 study," said Richard Kenney, M.D., Sonnet's Chief Medical Officer. "The PK and PD from 3 cohorts have been formally simulated to predict the levels of the most responsive cytokines. Interferon gamma (IFNg) levels rose after SON-1010 dosing as expected, but with lower peak elevations and much longer decay than those observed historically for rhIL-12, which correlates with better tumor control in preclinical models. Linking IL-12 to the FHAB is designed to permit use of higher doses of this cytokine without triggering unacceptable toxicity, allowing us to safely induce a successful local immune response to IL-12 in the TME."
https://finance.yahoo.com/news/sonnet-biotherapeutics-announces-pharmacokinetic-pharmacodynamic-130000814.html
If ENSC can pull off the typical 3 day candle run it could easily be over $2.
Not that I'm being greedy.
Liking the looks of SONN 1.29 & EVAX 1.60.
SONN daily
SONN
EVAX daily
EVAX
Early look at ENSC .7449...
ENSC daily
Trend lines look to be holding up nicely.
SONN daily
See how she plays the next few days.
NEWS! Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer
https://finance.yahoo.com/news/sonnet-biotherapeutics-announces-collaboration-roche-130000311.html
$SONN premarket mover Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer
https://finance.yahoo.com/news/sonnet-biotherapeutics-announces-collaboration-roche-130000311.html
They've got things happening, just not getting their name out there.
Bottom setting up nicely.
Looking good!!
This has been quite the disappointment for sure.
1.64 Some may think this is a discount. See how the chart sets up.
We'll see how this works out with the split coming. I've seen a couple RS's go ballistic lately.
Figured EVAX gap would fill. Took a bite 1.80. Looks like I'll take another bite lower.
SCYX bottom cracked. I was patient. Watching.
I kept some ammo just in case. We'll have to see how this goes thru Christmas I think. Getting the sideways treatment. Any spark of momentum could easily put this back over the $.